The 29 references in paper V. Arkhipov V., D. Arkhipova E., N. Lazareva B., В. Архипов В., Д. Архипова Е., Н. Лазарева Б. (2016) “Новые ингаляционные устройства для терапии хронической обструктивной болезни легких // Novel inhalation devices for treatment of chronic obstructive pulmonary disease” / spz:neicon:pulmonology:y:2016:i:3:p:352-356

1
Laube B.L., Janssens H.M., de Jongh F.H. et al. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J.2011; 37 (6): 1308–1331.
(check this in PDF content)
2
Rootmensen G.N., van Keimpema A.R., Jansen H.M., de Haan R.J. Predictors of incorrect inhalation technique in patients with asthma or COPD: a study using a validated videotaped scoring method. J. Aerosol. Med. Pulm. Drug Deliv.2010; 23 (5): 323–328.
(check this in PDF content)
3
Pothirat C., Chaiwong W., Phetsuk N. et al. Evaluating inhaler use technique in COPD patients. Int. J. Chron. Obstruct. Pulm. Dis. 2015; 10: 1291–1298.
(check this in PDF content)
4
Alaboud A., Assi K.H., and Chrystyn H. In vitro character" ization of the emitted dose from the foradil Aerolizer to identify the influence of inhalation flow, inhalation volume and the number of inhalations per dose. Respiratory Drug Delivery. 2012; 3: 803–806.
(check this in PDF content)
5
Azouz W., Chetcuti P., Hosker H.S. et al. The inhalation characteristics of patients when they use different dry pow" der inhalers. J. Aerosol. Med. Pulm. Drug Deliv.2015; 28 (1): 35–42.
(check this in PDF content)
6
Usmani O.S., Biddiscombe M.F., Barnes P.J. Regional lung deposition and bronchodilator response as a function of beta2"agonist particle size. Am. J. Respir. Crit. Care Med. 2005; 172 (12): 1497–1504.
(check this in PDF content)
7
Colice G., Martin R.J., Israel E. et al. Asthma outcomes and costs of therapy with extrafine beclomethasone and flu" ticasone. J. Allergy Clin. Immunol. 2013; 132 (1): 45–54.
(check this in PDF content)
8
Zanen P., Go L.T., Lammers J.W. Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax. 1996; 51 (10): 977–980.
(check this in PDF content)
9
Criée C.P., Meyer T., Petro W. et al. In vitro comparison of two delivery devices for administering formoterol: Foradil P and formoterol ratiopharm single"dose capsule inhaler. J. Aerosol. Med.2006; 19 (4): 466–472.
(check this in PDF content)
10
Colthorpe P., Voshaarb T., Kieckbusch T. et al. Delivery characteristics of a low"resistance dry"powder inhaler used to deliver the longacting muscarinic antagonist glycopyrro" nium.J. Drug Ass.2013; 2: 11–16.
(check this in PDF content)
11
Chapman K.R., Fogarty C.M., Peckitt C. et al. Delivery characteristics and patients' handling of two single"dose dry"powder inhalers used in COPD. Int. J. Chron. Obstruct. Pulm. Dis.2011; 6: 353–363.
(check this in PDF content)
12
Demoly P., Hagedoorn P., de Boer A.H., Frijlink H.W. The clinical relevance of dry powder inhaler performance for drug delivery. Respir. Med. 2014; 108 (8): 1195–1203. Рис. 2. Распределение препарата после ингаляции через ДАИ, Турбухалер и Респимат [27] Figure 2. Particle distribution after inhalation via dosing aerosol inhaler, Turbuhaler and Respimat [27]
(check this in PDF content)
13
Malmberg L.P., RytiläP., Happonen P., Haahtela T. Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters. Int. J. Chron. Obstruct. Pulm. Dis. 2010; 5: 257–262.
(check this in PDF content)
14
Weuthen T., Roeder S., Brand P. et al. In vitro testing of two formoterol dry powder inhalers at different flow rates. J. Aerosol. Med. 2002; 15 (3): 297–303.
(check this in PDF content)
15
Alaboud S.S. In"vitro inhalation performance for for" moterol dry powder and metred dose inhalers. University of Bradford; 2011. https://bradscholars.brad.ac.uk/bitstream/ handle/10454/5686/Final_Ph.D12.4.2012pdf.pdf?sequence=1 Date last accessed: June 14, 2016.
(check this in PDF content)
16
Hamilton M., Leggett R., Pang C. et al. In vitro dosing per" formance of the ellipta dry powder inhaler using asthma and COPD patient inhalation profiles replicated with the elec" tronic lung (eLung™). J. Aerosol. Med. Pulm. Drug Deliv. 2015; 28 (6): 498–506.
(check this in PDF content)
17
Ciciliani A., Wachtel H., Langguth P. Comparing Respimat®Soft Mist™ inhaler and DPI aerosol deposition by combined in vitro measurements and CFD simulations. Respir. Drug Delivery. 2014; 2: 453–456.
(check this in PDF content)
18
Newman S.P., Sutton D.J., Segarra R. et al. Lung deposi" tion of aclidinium bromide from Genuair, a multidose dry powder inhaler. Respiration. 2009; 78 (3): 322–328.
(check this in PDF content)
19
Corradi M., Chrystyn H., Cosio B.G. et al. NEXThaler, an innovative dry powder inhaler delivering an extrafine fixed combination of beclometasone and formoterol to treat large and small airways in asthma. Exp. Opin. Drug Deliv.2014; 11 (9): 1497–1506.
(check this in PDF content)
20
Scichilone N. Asthma control: the right inhaler for the right patient. Adv. Ther. 2015; 32 (4): 285–292.
(check this in PDF content)
21
Pasquali I. et al. Poster presentation at the 2012 AAPS Annual Meeting and Exposition, October 14–18, 2012; Chicago. Poster: M1150.
(check this in PDF content)
22
Newman S.P. Principles of metered"dose inhaler design. Respir. Care. 2005; 50 (9): 1177–1790.
(check this in PDF content)
23
Leach C.L., Davidson P.J., Boudreau R.J. Improved airway targeting with the CFC"free HFA"beclomethasone metered" dose inhaler compared with CFC"beclomethasone. Eur. Respir. J.1998; 12 (6): 1346–1353.
(check this in PDF content)
24
Hochrainer D., Hölz H., Kreher C. et al. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers.J. Aerosol. Med. 2005; 18 (3): 273–282.
(check this in PDF content)
25
Melani A.S., Bonavia M., Cilenti V. et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir. Med.2011; 105 (6): 930–938.
(check this in PDF content)
26
Pitcairn G., Reader S., Pavia D., Newman S. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J. Aerosol. Med. 2005; 18 (3): 264–272.
(check this in PDF content)
27
Ciciliani A., Wachtel H., Langguth P. Comparing Respimat Soft Mist inhaler and DPI aerosol deposition by combined in vitro measurements and CFD simulations. Respir. Drug Delivery.2014; 2: 453–456.
(check this in PDF content)
28
Ciciliani A., Wachtel H., Heussel C., Langguth P. Evalua" tion of Respimat Soft Mist inhaler based on in vitro meas" urements and CFD simulations. Respir. Drug Delivery.2015; 2: 357–362.
(check this in PDF content)
29
Noord J.A., Cornelissen P.J., Aumann J.L. et al. The efficacy of tiotropium administered via Respimat Soft Mist inhaler or HandiHaler in COPD patients. Respir. Med. 2009; 103 (1): 22–29. Поступила 10.06.16
(check this in PDF content)